Novo Nordisk A/S — Company profile
Healthcare · Drug Manufacturers - General · Denmark
Last price 39.14 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 171.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Details
| Name | Novo Nordisk A/S |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 66700 |
| Founded | 1923 |
| Ceo | Maziar Doustdar |
| Country | Denmark |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| Isin | US6701002056 |
| Cusip | 670100205 |
| Cik | 0000353278 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Elin Jager | SVice President, Chief of Staff to Chief Executive Officer, Corporate Strategy and Sustainability and Member of Management Board |
| Maziar Mike Doustdar B.A. | President, Chief Executive Officer and Member of the Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer and Member of the Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Research & Development, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | Executive Vice President of People, Organisation and Corporate Affairs and Member of Management Board |
| Thilde Hummel Bogebjerg | Executive Vice President of Enterprise IT and Quality and Member of Management Board |
| John F. Kuckelman | SVice President, Group General Counsel, Global Legal, IP and Security and Member of Management Board |
| Emil Kongshoej Larsen | Executive Vice President of International Operations and Member of Management Board |
| Jamey Millar | Executive Vice President of US Operations and Member of Management Board |
| Hong Chow | Executive Vice President of Product and Portfolio Strategy and Member of Management Board |
Contact
| Address | Novo Alle 1, Bagsvaerd, 2880, Denmark |
| Phone | 45 44 44 88 88 |
| Website | https://www.novonordisk.com |